Physicochemical characterization of dipeptidyl peptidase-4 inhibitor alogliptin in physical mixtures with excipients

被引:0
|
作者
Charise Dallazem Bertol
Rafael Nicolay Pereira
Cassiana Mendes
Amarilis Scremim Paulino
Marcos Antônio Segatto Silva
Pedro Eduardo Froehlich
机构
[1] Universidade de Passo Fundo,Curso de Farmácia, Instituto de Ciências Biológicas
[2] Universidade Federal do Rio Grande do Sul,Programa de Pós
[3] Universidade Federal de Santa Catarina,graduação em Ciências Farmacêuticas, Laboratório de Produção de Substâncias Químicas de Referência
关键词
Alogliptin; Compatibility studies; Crystallinity; Thermoanalysis;
D O I
暂无
中图分类号
学科分类号
摘要
Alogliptin (ALG) is a hypoglycemic drug used in diabetes which inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), preventing the degradation of incretins, stimulating insulin secretion. The physicochemical characteristics of ALG were evaluated by differential scanning calorimetry (DSC), thermogravimetry (TG) and scanning electron microscopy equipped with energy-dispersive X-ray spectrometer (SEM/EDS). The compatibility studies were carried out between ALG and excipients (physical mixtures, 1:1) using DSC, TG, diffuse reflectance Fourier transform infrared spectroscopy (FTIR), X-ray powder diffraction (XRPD) and hot-stage microscopy. ALG presented purity near to 99%, melted in the range of 179.4–187.2 °C, followed by decomposition which started in 198.0 °C. SEM/EMS analysis of ALG presented irregular crystals and traces of impurities as copper and lead. DSC investigations obtained by physical mixtures showed minor alterations in the melting ranges of ALG with mannitol, magnesium stearate and commercial tablets. Solubilization of ALG in the fused excipient was observed by hot-stage microscopy between mannitol and ALG, and in tablets. The interaction observed in the mixture with magnesium stearate is due to the melting of the excipient and drug separately, first the excipient and then the drug. FTIR showed additional bands related to the excipients. XRPD proved that ALG has a crystal form and no alterations in the ALG profile were observed after the mixtures. ALG was compatible with all excipients tested. These results were important to understand the characteristics, stability and compatibility of the drug, and proved to be useful in preformulation studies.
引用
收藏
页码:1575 / 1584
页数:9
相关论文
共 50 条
  • [31] Renoprotective Effect of a Dipeptidyl Peptidase-4 Inhibitor on Aging Mice
    Ban, Tae H.
    Kim, Eun N.
    Kim, Min Y.
    Lim, Ji H.
    Lee, Jong H.
    Kim, Hyung D.
    Yoon, Hye E.
    Park, Cheol W.
    Choi, Bum S.
    AGING AND DISEASE, 2020, 11 (03): : 588 - 602
  • [32] Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes
    Yanai, Hidekatsu
    Masui, Yoshinori
    Yoshikawa, Reo
    Kunimatsu, Junwa
    Kaneko, Hiroshi
    WORLD JOURNAL OF DIABETES, 2010, 1 (03): : 99 - 100
  • [33] Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor
    David W. Boulton
    Clinical Pharmacokinetics, 2017, 56 : 11 - 24
  • [34] Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor
    Kano, Yasuhiro
    Kato, Miyuki
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (20) : E705 - E705
  • [35] Dipeptidyl Peptidase-4 Inhibitor Another Player for Cardiovascular Protection
    Murohara, Toyoaki
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (03) : 277 - 279
  • [36] Effect of dipeptidyl peptidase-4 inhibitor on emphysema model in mice
    Joo, H.
    Kim, J. W.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [37] Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
    Tasanen, Kaisa
    Varpuluoma, Outi
    Nishie, Wataru
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [38] A dipeptidyl peptidase-4 inhibitor reverses diabetes in NOD mice
    Suarez-Pinzon, Wilma L.
    Rabinovitch, Alex
    DIABETES, 2007, 56 : A419 - A419
  • [39] Resolution of Gastroparesis Symptoms With the Removal of a Dipeptidyl Peptidase-4 Inhibitor
    Nuvvula, Sri
    Rau, Prashanth
    Belkin, Dimitri
    Houghton, Jean Marie
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S1289 - S1289
  • [40] Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats
    Bao, Wulan
    Morimoto, Keisuke
    Hasegawa, Tomomi
    Sasaki, Naoto
    Yamashita, Tomoya
    Hirata, Kenichi
    Okita, Yutaka
    Okada, Kenji
    JOURNAL OF VASCULAR SURGERY, 2014, 59 (04) : 1098 - 1108